Neurology News

Intra-arterial alteplase after successful reperfusion with mechanical thrombectomy for large vessel occlusion acute ischemic stroke conferred better neurological outcomes compared with placebo, a speaker reported.

Bayer announced that asundexian, a novel factor XIa inhibitor being evaluated for secondary prevention of stroke, has received fast track designation from the FDA.

Administration of low-dose IV tenecteplase in the 4.5 to 24 hours after stroke symptom onset seemed to be safe and effective in the reperfusion and recanalization of occluded large cerebral vessels, a speaker reported.

One important success factor for physicians when it comes to investing is understanding how they are unlike most U.S. retail investors. Physicians have a level of education, income and, typically, net worth that far exceed those of most investors in our country. It is also important to recognize all investors, regardless of education or experience, are influenced by the media. The combination of these factors can create added challenges for physicians when deciding how to allocate their assets.

In a new statement, the American Heart Association presented scientific evidence that challenges the belief that marijuana is harmless and highlights uncertainty about the drug’s effect on brain health.

White matter hyperintensity volumes at 1 year strongly correlated with contemporaneous cognitive scores after stroke, according to study results published in Neurology.

In patients with cerebral venous thrombosis, direct oral anticoagulants were safer than warfarin without compromising efficacy, researchers reported at the International Stroke Conference.

Intensive periodontal treatment for gum disease after stroke or transient ischemic attack did not affect the rate of vascular events at 1 year compared with standard treatment, a speaker reported.

Compared with standard care, use of mobile units sharply increased the odds of positive outcomes and reduced treatment times for acute ischemic stroke, according to a systematic review and meta-analysis published in JAMA Neurology.

The FDA has granted investigational device exemption to clinical-stage medical device company CereVasc for a pilot trial of its eShunt System in patients with normal pressure hydrocephalus.